-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

615.O2.6 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Advances in Mutation-targeted Therapy for AML

Symposia: Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Biological therapies, Antibody Therapy, Acute Myeloid Malignancies, AML, adult, Non-Biological therapies, APL, Clinical Research, Chemotherapy, Combination therapy, Diseases, Therapies, real-world evidence, Adverse Events, Monoclonal Antibody Therapy, Myeloid Malignancies, Study Population, Human, Minimal Residual Disease
Monday, December 12, 2022: 2:45 PM-4:15 PM
R02-R05 (Ernest N. Morial Convention Center)
Moderators:
Abhay Singh, MD, MPH, Taussig Cancer Institute, Leukemia Program, Cleveland Clinic Foundation and Justin Watts, MD, Sylvester Comprehensive Cancer Center
Disclosures:
No relevant conflicts of interest to declare.
These six abstracts report on advances in targeted therapy in AML, including targeted inhibition of FLT3, IDH2, and PML-RARA, sorafenib use in CBF-AML, and gemtuzumab in NPM1-mutant AML.
2:45 PM

Jad Othman, MBBS1,2, Nicola Potter, PhD2*, Katya Mokretar3*, David Taussig, MD, PhD4*, Anjum Khan5*, Pramila Krishnamurthy, MD6*, Anne-Louise Latif7*, Paul Cahalin, MA MRCP FRCPath8*, James Aries9*, Mariam Amer10*, Edward Belsham, FRCPath, MB11*, Eibhlin Conneally, MB, PhD, MRCP, FRCPath12, Charles Craddock13, Dominic Culligan14*, Mike Dennis, MD, MRCP, FRCPath15, Caroline Duncan, FRPATH, MBBS, MRCP,16*, Caroline Furness17*, Paraskevi Gkreka, MD, PhD18*, Katherine Hodgson19*, Wendy Ingram20*, Andrew King21*, Panagiotis Kottaridis, MD, PhD22*, Mary Frances McMullin, MD, FRCPath, FRCP23, Unmesh Mohite24*, Loretta Ngu25*, Katharine Patrick26*, Tom Rider27*, Wing Roberts28*, Marianne Tang Severinsen, MD, PhD29*, Neill Storrar, MBBChir30*, Tom Taylor31*, Nigel H. Russell, MD1 and Richard Dillon, MA PhD MRCP FRCPath1,32

1Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
2Department of Medical and Molecular Genetics, King's College London, London, United Kingdom
3Cancer Genetics, Viapath, London, ENG, GBR
4The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
5St James's Institute of Oncology, The Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
6King’s College Hospital, London, United Kingdom
7Department of Haematology, Queen Elizabeth University Hospital, Glasgow, United Kingdom
8Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, United Kingdom
9Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
10University Hospital Southampton, Southampton, United Kingdom
11Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom
12Haematology, St. James' Hospital, Dublin, Ireland
13Centre for Clinical Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
14Dep. of Haematology, Aberdeen Royal Infirmary, Aberdeen, CA, United Kingdom
15Haematology, The Christie NHS Foundation Trust, Manchester, United Kingdom
16Raigmore Hospita, Inverness, United Kingdom
17Royal Marsden Hospital, London, United Kingdom
18Princess Royal University Hospital, London, United Kingdom
19University Hospital Leicester, Leicester, United Kingdom
20Department of Haematology, University Hospital Wales, Cardiff, United Kingdom
21Addenbrooke's Hospital, Cambridge, United Kingdom
22University College London Hospital NHS Foundation Trust, London, GBR
23Centre for Medical Education, Queen's University, Belfast, United Kingdom
24Singleton Hospital, Swansea, GBR
25Royal Devon & Exeter NHS Foundation Trust, Exeter, United Kingdom
26Sheffield Childrens NHS Foundation Trust, Sheffield, United Kingdom
27The Royal Sussex County Hospital, Brighton, United Kingdom
28Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom
29Aalborg University Hospital, Aalborg, Denmark
30Department of Haematology, NHS Lothian, Edinburgh, United Kingdom
31Nottingham University Hospital, Nottingham, United Kingdom
32Department of Medical and Molecular Genetics, King's College London, London, ENG, United Kingdom

3:00 PM

Pengcheng Shi1*, Xi Jia2*, Naying Liao3*, Yin Changxin4*, Huan Li1*, Xuejie Jiang, MD5*, Guopan Yu, MD5*, Jieyu Ye5*, Hong Qu6*, Yu Zhan7*, Chunju Wen8*, Yu Zhang5* and Qifa Liu, MD9

1Department of Hematology, Nanfang Hospital, Southern medical University, Guangzhou, China
2Nanfang Hospital, Southern medical University, Guangzhou, AL, China
3Nanfang Hospital, Southern medical University, Guangzhou, China
4nanfang hospital, southern mediacl university, guangzhou, China
5Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
6Department of Hematology,, Panyu,Guangzhou, Guangdong, China, Pan Yu Central Hospital, Guangzhou, China
7gaungzhou twelfth people's hospital, guangzhou, China
8ganzhou people's hospital, ganzhou, China
9Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

3:15 PM

Nicholas Short, MD1, Courtney D. DiNardo, MD, MSCE2, Naval Daver, MD2, Walid Macaron, MD, MSc2*, Musa Yilmaz, MD3, Gautam Borthakur, MD2, Guillermo Montalban-Bravo, MD2, Guillermo Garcia-Manero, MD4, Ghayas C. Issa, MD2, Koji Sasaki, MD2, Philip A. Thompson, MBBS2, Jan A. Burger, MD, PhD1, Abhishek Maiti, MBBS2, Yesid Alvarado, MD2, Monica Kwari, BSN2, Ricardo Delumpa, BSN2*, Jennifer Thankachan2*, Ejiroghene Mayor, BSN, RN2*, Christopher Loiselle, BS2*, Anna Milton2*, Glenda Banks2*, Tapan M. Kadia, MD3, Marina Konopleva, MD, PhD1, Hagop Kantarjian, MD5 and Farhad Ravandi, MD2

1Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
3Department of Leukemia, MD Anderson Cancer Center, Houston, TX
4Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
5Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

3:30 PM

Hartmut Döhner, MD1, Daniela Weber, MSc2*, Julia Krzykalla, PhD3*, Walter Fiedler, MD4, Michael W.M. Kühn, MD5*, Thomas Schroeder6*, Karin Mayer, MD7*, Michael Lübbert, MD8, Mohammad Wattad, MD9, Katharina Götze10*, Lars Fransecky, MD11*, Elisabeth Koller, MD12*, Gerald Wulf, MD13*, Jan Schleicher, MD14*, Mark Ringhoffer, MD15*, Richard Greil, MD16, Bernd Hertenstein, MD17*, Jürgen Krauter, MD, PhD18*, Uwe M. Martens, MD19, David Nachbaur, MD20*, Maisun Abu Samra, M.D.21*, Sigrid Machherndl-Spandl, MD22*, Nadezda Basara, MD23, Claudia Leis2*, Anika Schrade, PhD1*, Silke Kapp-Schwoerer, MD1*, Lars Bullinger, MD24, Felicitas R. Thol, MD25, Michael Heuser, MD25, Peter Paschka, MD1, Verena I. Gaidzik, MD1, Maral Saadati, PhD26*, Axel Benner27*, Richard F. Schlenk, MD2,28, Konstanze Döhner, MD29 and Arnold Ganser, MD30*

1Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
2Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany
3Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany
4Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Cancer Center Hamburg, University Hospital Eppendorf, Hamburg, Germany
5Department of Hematology, Oncology and Pneumology, University Medical Center, Johannes Gutenberg-University, Mainz, Germany
6Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Medical Faculty, Düsseldorf, Germany
7Department of Internal Medicine III, University Hospital of Bonn, Bonn, Germany
8Department of Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, Freiburg, Germany
9Kliniken Essen Sued, Essen, Germany
10Department of Internal Medicine III, Technical University of Munich, Klinikum rechts der Isar, Munich, Germany
11Department of Internal Medicine II, University Hospital Schleswig-Holstein, Kiel, Germany
123rd Medical Department for Hematology and Oncology, Hanusch Hospital, Vienna, Austria
13Department of Hematology and Oncology, Georg-August-University of Göttingen, Göttingen, Germany
14Department of Hematology and Oncology, Katharinenhospital Stuttgart, Stuttgart, Germany
15Department of Internal Medicine III, Municipal Hospital of Karlsruhe, Karlsruhe, Germany
163rd Medical Department, Paracelsus Medical University, Salzburg Cancer Research Institute-CCCIT and Cancer Cluster Salzburg, Salzburg, Austria
17Klinikum Bremen Mitte, Bremen, Germany
18Department of Internal Medicine III, Städtisches Klinikum Braunschweig, Braunschweig, Germany
19Department of Internal Medicine III, SLK-Clinics Heilbronn, Heilbronn, Germany
20University Hospital for Internal Medicine V, Haematology and Oncology, Innsbruck Medical University, Innsbruck, Austria
21University of Gießen, Gießen, Germany
22Ordensklinikum Linz Elisabethinen, Linz, Austria
23Medizinische Klinik I, Malteser Krankenhaus St. Franziskus-Hospital, Flensburg, Germany
24Department of Hematology, Oncology and Tumorimmunology (Campus Virchow-Klinikum), Charite University Berlin, Berlin, Germany
25Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
26Saadati Solutions, Ladenburg, Germany
27Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany
28National Center of Tumor Diseases, Heidelberg, Heidelberg, Germany
29Division of Hematology and Oncology, University Hospital Ulm, Ulm, Germany
30Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hanover, Germany

3:45 PM

Huaiyu Wang, MD1, Shu Chen1*, Xiaojuan Zhang1*, Xinhua Lu1*, Sha Gong1*, David Wald, PhD, MD2*, Haitao Zhang, MD1* and Jing Li1*

1The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
2Case Western Reserve University, Cleveland, OH

4:00 PM

Eytan Stein, MD1, Sheng F Cai, MD, PhD2, Ying Huang, MS, MA3*, Andrew Dunbar, MD4, Maria R. Baer, MD5, Wendy Stock, MD6, Tibor Kovacsovics, MD7, William G. Blum, MD8, Gary J. Schiller, MD9, Rebecca L. Olin, MD10, James M. Foran, MD11, Mark R. Litzow, MD12, Tara L. Lin, MD13, Prapti A. Patel, MD14*, Matthew C. Foster, MD15, Michael M. Boyiadzis, MD16, Robert H. Collins, M.D.17, Jordan Chervin18*, Abigail B. Shoben, PhD19*, Jo-Anne Vergilio, MD20*, Nyla A. Heerema, PhD21, Leonard Rosenberg, PhD RPh22*, Timothy Chen, PhD23*, Ashley O. Yocum, PhD24*, Franchesca Druggan, MSc25*, Sonja Marcus, MPH26*, Mona Stefanos19*, Molly Martycz19*, Brian J. Druker27, Alice S. Mims, MD3, Uma Borate, MD28, Amy Burd, PhD29, John C. Byrd, MD30 and Ross L. Levine, MD31

1Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
2Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY
3Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH
4Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
5University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD
6University of Chicago, Chicago, IL
7Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
8Department of Hematology and Oncology, Winship Cancer Institute of Emory University, Atlanta, GA
9David Geffen School of Medicine at UCLA, Los Angeles, CA
10University of California, San Francisco, San Francisco, CA
11Division of Hematology/Oncology and Blood and Marrow Transplanation and Cellular Therapy, Mayo Clinic, Jacksonville, FL
12Division of Hematology, Mayo Clinic, Rochester, MN
13University of Kansas, Westwood, KS
14Division of Hematologic Malignancies, University of Texas Southwestern Medical Center, Dallas, TX
15Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
16Univ. of Pittsburgh Cancer Inst., Pittsburgh, PA
17Division of Hematology/Oncology, Department of Internal Medicine, University of Texas Southwestern, Dallas, TX
18Memorial Sloan Kettering Cancer Center, New York, NY
19The Ohio State University Comprehensive Cancer Center, Columbus, OH
20Foundation Medicine, Cambridge, MA
21Department of Pathology, The Ohio State University, Columbus, OH
22Leukemia & Lymphoma Society, Mount Laurel, NJ
23Department of Internal Medicine, Division of Hematology, College of Medicine, The Ohio State University, Columbus, OH
24The Leukemia & Lymphoma Society, Rye Brook, NY
25The Ohio State University, Columbus, OH
26Leukemia & Lymphoma Society, Rye Brook, NY
27Knight Cancer Institute, Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR
28Division of Hematology, The Ohio State University, Columbus, OH
29The Leukemia & Lymphoma Society, White Plains, NY
30Department of Internal Medicine, University of Cincinnati, Cincinnati, OH
31Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY

*signifies non-member of ASH